In January 2021, the healthcare industry reported 70 deals worth $6.2 billion as compared to last 12-month average (January 2020 to December 2020) of 87 deals worth $17.1 billion.
Chasing a big market opportunity that recently tripped up another vaccine developer, Bavarian Nordic reports that a single shot of its universal respiratory syncytial virus (RSV) candidate can elicit a significant immune response shortly after vaccination
Nordic Nanovector CEO Luigi Costa indicated that the company, which is developing new ways to treat blood cancers, has seen increasing interest from potential buyers, as reported in NASDAQ.